Hip-1: Difference between revisions
No edit summary |
m (Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +)) |
||
Line 1: | Line 1: | ||
{{SI}} | {{SI}} | ||
==Overview== | ==Overview== | ||
Line 6: | Line 6: | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
{{WH}} | {{WH}} |
Latest revision as of 15:59, 9 August 2012
WikiDoc Resources for Hip-1 |
Articles |
---|
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Hip-1 at Clinical Trials.gov Clinical Trials on Hip-1 at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Hip-1
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Directions to Hospitals Treating Hip-1 Risk calculators and risk factors for Hip-1
|
Healthcare Provider Resources |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Overview
Huntingtin Interacting Protein or Hip-1 for short is a protein that interacts with the huntingtin protein. It is known to contain a domain homologous to the death effector domains (DED) found on proteins involved in apoptosis. It is believed that accumulation of high levels of the free form of this protein in the cell is one of the mechanisms by which neuron cell death is caused in Huntington's Disease (via the caspase-3 route).